Additional file 4 of Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Additional file 4: Supplementary Table 2. EC50 and EC90 values of capmatinib (cap) and crizotinib (cri) following 3-day dose response assays. To calculate unbound EC50 and EC90 values, total values were multiplied with unbound drug fractions in culture media (Table 1).

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Zuckermann, Marc, He, Chen, Andrews, Jared, Bagchi, Aditi, Sloan-Henry, Roketa, Bianski, Brandon, Xie, Jia, Wang, Yingzhe, Twarog, Nathaniel, Onar-Thomas, Arzu, Ernst, Kati J., Yang, Lei, Li, Yong, Zhu, Xiaoyan, Ocasio, Jennifer K., Budd, Kaitlin M., Dalton, James, Li, Xiaoyu, Chepyala, Divyabharathi, Zhang, Junyuan, Xu, Ke, Hover, Laura, Roach, Jordan T., Chan, Kenneth Chun-Ho, Hofmann, Nina, McKinnon, Peter J., Pfister, Stefan M., Shelat, Anang A., Rankovic, Zoran, Freeman, Burgess B., Chiang, Jason, Jones, David T. W., Tinkle, Christopher L., Baker, Suzanne J.
Format:	Dataset
Sprache:	eng
Schlagworte:	Biological Sciences not elsewhere classified Cancer Mathematical Sciences not elsewhere classified Medicine
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Additional file 4: Supplementary Table 2. EC50 and EC90 values of capmatinib (cap) and crizotinib (cri) following 3-day dose response assays. To calculate unbound EC50 and EC90 values, total values were multiplied with unbound drug fractions in culture media (Table 1).
DOI:	10.6084/m9.figshare.26730895